Examining body composition and metabolic changes in advanced lung cancer
The Clinical Significance of Metabolic Adipo-myokines and Alterations of Body Composition in Patients With End Stage Lung Cancer
This study looks at how changes in body composition and certain proteins in the blood affect people with advanced lung cancer who are undergoing chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 20 Years to 100 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Kaohsiung City) |
| Trial ID | NCT06060262 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the relationship between changes in body composition, serum adipo-myokines, and the adverse effects of chemotherapy in patients with end-stage lung cancer. By monitoring these factors, the researchers hope to understand how they correlate with clinical outcomes and the prognosis of lung cancer. The study will involve adults diagnosed with stage III to IV lung cancer, focusing on the biochemical functions of skeletal muscle and its impact on cancer cachexia and malnutrition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 20 years old with a diagnosis of stage III to IV lung cancer and a daily performance status of 0-2.
Not a fit: Patients with cardiac stents or pacemakers may not benefit from this study due to exclusion criteria.
Why it matters
Potential benefit: If successful, this study could provide insights into improving the management of lung cancer patients by addressing malnutrition and cachexia.
How similar studies have performed: While this study explores a specific association, similar studies have shown promising results in understanding the role of body composition and metabolic factors in cancer outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosis of lung cancer stage III to stage IV 2. Adults over 20 years old 3. Daily performance status of 0- 2 Exclusion Criteria: 1. Cardiac stents or pacemakers
Where this trial is running
Kaohsiung City
- Kaohsiung Chang Gung Memorial Hospital — Kaohsiung City, Taiwan (Recruiting)
Study contacts
- Principal investigator: Tseng Chia-Cheng — Chang Gung Memorial Hospital
- Study coordinator: Tseng Chia-Cheng
- Email: cctseng@hotmail.com.tw
- Phone: +886 7 731 7123
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.